Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Martin Taylor-Rowan; Ahmed A Alharthi; Anna H Noel-Storr; Phyo K Myint; Carrie Stewart; Jenny McCleery; Terry J Quinn

doi:10.1002/14651858.CD015405.pub2

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Martin Taylor-Rowan^* (Corresponding Author), Ahmed A Alharthi, Anna H Noel-Storr, Phyo K Myint, Carrie Stewart, Jenny McCleery, Terry J Quinn

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:Primary objective• To assess the efficacy and safety of anticholinergic medication reduction interventions to improve cognitive outcomes in bothcognitively healthy older adults and older adults with pre-existing cognitive issues.Secondary objectives• To compare the effectiveness of different types of reduction interventions (e.g. pharmacist-led versus GP-led; educational versus audit and feedback) in reducing overall anticholinergic burden.• To establish optimal duration of anticholinergic reduction interventions; sustainability, and lessons learned for upscaling• To compare results according to differing anticholinergic scales used in medication reduction intervention trials.• To assess the efficacy of anticholinergic medication reduction interventions to improve other clinical outcomes, including mortality, quality of life, clinical global impression, physical function, institutionalisation, falls, cardiovascular diseases, and neurobehavioral outcomes in people with pre-existing cognitive impairment. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Original language	English
Article number	CD015405
Number of pages	18
Journal	Cochrane Database of Systematic Reviews
Volume	2022
Issue number	12
DOIs	https://doi.org/10.1002/14651858.CD015405.pub2 https://doi.org/10.1002/14651858.cd015405
Publication status	Published - 8 Dec 2023

Bibliographical note

Acknowledgement
We would like to thank peer reviewers Roy Soiza and Edwin Tanand consumer reviewer Cathie Hofstetter for their comments andfeedback

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.CD015405.pub2Licence: Unspecified
10.1002/14651858.cd015405Licence: Unspecified

Taylor_etal_CDR_Anticholinergic_Deprescribing_Interventions_VoRFinal published version, 502 KBLicence: Other

Cite this

Taylor-Rowan, M., Alharthi, A. A., Noel-Storr, A. H., Myint, P. K., Stewart, C., McCleery, J., & Quinn, T. J. (2023). Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment. Cochrane Database of Systematic Reviews, 2022(12), Article CD015405. https://doi.org/10.1002/14651858.CD015405.pub2, https://doi.org/10.1002/14651858.cd015405

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment. / Taylor-Rowan, Martin (Corresponding Author); Alharthi, Ahmed A; Noel-Storr, Anna H et al.
In: Cochrane Database of Systematic Reviews, Vol. 2022, No. 12, CD015405, 08.12.2023.

Research output: Contribution to journal › Article › peer-review

Taylor-Rowan, M, Alharthi, AA, Noel-Storr, AH, Myint, PK , Stewart, C, McCleery, J & Quinn, TJ 2023, 'Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment', Cochrane Database of Systematic Reviews, vol. 2022, no. 12, CD015405. https://doi.org/10.1002/14651858.CD015405.pub2, https://doi.org/10.1002/14651858.cd015405

Taylor-Rowan M, Alharthi AA, Noel-Storr AH, Myint PK , Stewart C, McCleery J et al. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment. Cochrane Database of Systematic Reviews. 2023 Dec 8;2022(12):CD015405. doi: 10.1002/14651858.CD015405.pub2, 10.1002/14651858.cd015405

@article{6c3d221a73b84580af0be1de20265d4b,

title = "Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment",

abstract = "ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:Primary objective• To assess the efficacy and safety of anticholinergic medication reduction interventions to improve cognitive outcomes in bothcognitively healthy older adults and older adults with pre-existing cognitive issues.Secondary objectives• To compare the effectiveness of different types of reduction interventions (e.g. pharmacist-led versus GP-led; educational versus audit and feedback) in reducing overall anticholinergic burden.• To establish optimal duration of anticholinergic reduction interventions; sustainability, and lessons learned for upscaling• To compare results according to differing anticholinergic scales used in medication reduction intervention trials.• To assess the efficacy of anticholinergic medication reduction interventions to improve other clinical outcomes, including mortality, quality of life, clinical global impression, physical function, institutionalisation, falls, cardiovascular diseases, and neurobehavioral outcomes in people with pre-existing cognitive impairment. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment",

author = "Martin Taylor-Rowan and Alharthi, {Ahmed A} and Noel-Storr, {Anna H} and Myint, {Phyo K} and Carrie Stewart and Jenny McCleery and Quinn, {Terry J}",

note = "Acknowledgement We would like to thank peer reviewers Roy Soiza and Edwin Tanand consumer reviewer Cathie Hofstetter for their comments andfeedback",

year = "2023",

month = dec,

day = "8",

doi = "10.1002/14651858.CD015405.pub2",

language = "English",

volume = "2022",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "Wiley",

number = "12",

}

TY - JOUR

T1 - Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

AU - Taylor-Rowan, Martin

AU - Alharthi, Ahmed A

AU - Noel-Storr, Anna H

AU - Myint, Phyo K

AU - Stewart, Carrie

AU - McCleery, Jenny

AU - Quinn, Terry J

N1 - Acknowledgement We would like to thank peer reviewers Roy Soiza and Edwin Tanand consumer reviewer Cathie Hofstetter for their comments andfeedback

PY - 2023/12/8

Y1 - 2023/12/8

N2 - ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:Primary objective• To assess the efficacy and safety of anticholinergic medication reduction interventions to improve cognitive outcomes in bothcognitively healthy older adults and older adults with pre-existing cognitive issues.Secondary objectives• To compare the effectiveness of different types of reduction interventions (e.g. pharmacist-led versus GP-led; educational versus audit and feedback) in reducing overall anticholinergic burden.• To establish optimal duration of anticholinergic reduction interventions; sustainability, and lessons learned for upscaling• To compare results according to differing anticholinergic scales used in medication reduction intervention trials.• To assess the efficacy of anticholinergic medication reduction interventions to improve other clinical outcomes, including mortality, quality of life, clinical global impression, physical function, institutionalisation, falls, cardiovascular diseases, and neurobehavioral outcomes in people with pre-existing cognitive impairment. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

AB - ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:Primary objective• To assess the efficacy and safety of anticholinergic medication reduction interventions to improve cognitive outcomes in bothcognitively healthy older adults and older adults with pre-existing cognitive issues.Secondary objectives• To compare the effectiveness of different types of reduction interventions (e.g. pharmacist-led versus GP-led; educational versus audit and feedback) in reducing overall anticholinergic burden.• To establish optimal duration of anticholinergic reduction interventions; sustainability, and lessons learned for upscaling• To compare results according to differing anticholinergic scales used in medication reduction intervention trials.• To assess the efficacy of anticholinergic medication reduction interventions to improve other clinical outcomes, including mortality, quality of life, clinical global impression, physical function, institutionalisation, falls, cardiovascular diseases, and neurobehavioral outcomes in people with pre-existing cognitive impairment. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

U2 - 10.1002/14651858.CD015405.pub2

DO - 10.1002/14651858.CD015405.pub2

M3 - Article

C2 - 38063254

SN - 1469-493X

VL - 2022

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 12

M1 - CD015405

ER -

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this